Aminolevulinic acid hydrochloride is under clinical development by SBI Pharmaceuticals and currently in Phase II for Anemia. According to GlobalData, Phase II drugs for Anemia have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aminolevulinic acid hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aminolevulinic acid hydrochloride overview
Aminolevulinic acid hydrochloride (5-ALA) is under development for the treatment of ischemia reperfusion injury, sideroblastic anemia, amnestic mild cognitive impairment. It is administered through oral route.
It was also under development for the treatment of early Alzheimer disease.
SBI Pharmaceuticals overview
SBI Pharmaceuticals (SBI Pharma), formerly SBI Alapromo, a subsidiary of SBI Holdings Inc, is a healthcare solution provider that develops and manufactures 5-ALA (5-Aminolevulinic Acid) based products in the areas of medicines for cancer cell identification and cancer diagnosis, cosmetics and skin-care products, and health food (dietary supplements). The company also develops and markets medical devices to various clinical sites. It provides products, which are used for the treatment of cancer diagnosis, hypertension, anemia, lifestyle related diseases and others. The company has presence in Bahrain and Japan. SBI Pharma is headquartered in Tokyo, Japan.
For a complete picture of Aminolevulinic acid hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.